In this study, we established an in-house database of yeast internal transcribed spacer (ITS) sequences. This database includes medically important as well as colonizing yeasts that frequently occur in the diagnostic laboratory. In a prospective study, we compared molecular identification with phenotypic identification by using the ID32C system (bioMérieux) for yeast strains that could not be identified by a combination of CHROMagar Candida and morphology on rice agar. In total, 113 yeast strains were included in the study. By sequence analysis, 98% of all strains were identified correctly to the species level. With the ID32C, 87% of all strains were identified correctly to the species or genus level, 7% of the isolates could not be identified, and 6% of the isolates were misidentified, most of them as Candida rugosa or Candida utilis. For a diagnostic algorithm, we suggest a three-step procedure which integrates morphological criteria, biochemical investigation, and sequence analysis of the ITS region.Yeast infections are increasing due to the growing number of immunocompromised and severely ill patients (5, 9). In addition, widespread use of antibiotics and invasive procedures facilitate infections with yeasts (18). Although Candida albicans is still the most frequently encountered yeast species, others have gained increasing importance in the last few years (1). Some species, such as Candida krusei (resistance to fluconazole) or Trichosporon sp. (reduced susceptibility to amphotericin B), may show inherent resistance to antimycotics (13). Rapid and accurate identification is thus essential for proper treatment. Various identification methods have been proposed in the past, including morphology, physiological properties, nucleic acid amplification, restriction fragment length polymorphism analysis, and sequencing (2).For molecular identification, we have chosen sequence analysis since this procedure is simple and can be fully automated. In addition, interpretation of nucleic acid sequences is straightforward and does not depend on too much expertise compared to morphological analyses. As target, we have chosen the internal transcribed spacer (ITS) region, which is located between the highly conserved genes coding for 18S and 28S rRNA. The ITS encompasses the two noncoding regions ITS1 and ITS2, which are separated by the highly conserved 5.8S rRNA gene (20). The ITS1 and ITS2 regions are more variable than the adjacent rRNA gene sequences and thus promise a better separation of closely related species. As the inspection of yeast ITS sequences which are available in the public database GenBank (NCBI) suggested that some entries are incorrect and because certain medically relevant species are not included, we decided to establish an in-house database. Since the number of known yeast species is enormous, we restricted our database to species occurring in the medical diagnostic laboratory.In this study, we compared sequence-based identification with conventional identification. Based on these results, we establish...
The implementation of internal transcribed spacer (ITS) sequencing for routine identification of molds in the diagnostic mycology laboratory was analyzed in a 5-year study. All mold isolates (n ؍ 6,900) recovered in our laboratory from 2005 to 2009 were included in this study. According to a defined work flow, which in addition to troublesome phenotypic identification takes clinical relevance into account, 233 isolates were subjected to ITS sequence analysis. Sequencing resulted in successful identification for 78.6% of the analyzed isolates (57.1% at species level, 21.5% at genus level). In comparison, extended in-depth phenotypic characterization of the isolates subjected to sequencing achieved taxonomic assignment for 47.6% of these, with a mere 13.3% at species level. Optimization of DNA extraction further improved the efficacy of molecular identification. This study is the first of its kind to testify to the systematic implementation of sequence-based identification procedures in the routine workup of mold isolates in the diagnostic mycology laboratory.
c Xpert-MTB/Rif is one of the most frequently used molecular screening tests for multidrug-resistant tuberculosis worldwide. We report false-negative assay results in the presence of rpoB Leu533Pro, which is associated with low-level phenotypic rifampin resistance. Accurate and timely confirmation of rifampin susceptibility results obtained with Xpert-MTB/Rif is imperative.T he accurate diagnosis of drug-resistant and multidrug-resistant (MDR) tuberculosis (TB) is imperative to initiate adequate treatment, to avoid transmission of the disease, and to prevent the development of further drug resistance. Because of its worldwide rollout and rapid implementation, the Xpert-MTB/Rif assay (Cepheid) has become one of the most frequently used molecular screening tests for TB and MDR TB in both resource-poor and resource-rich countries (1). Recently, a 67-year-old Swissborn male patient was admitted to a secondary-care hospital in Switzerland with clinical and radiologic suspicion of pulmonary TB. Rapid testing by Xpert-MTB/Rif showed the presence of Mycobacterium tuberculosis complex in two sputum samples (Table 1; samples 1 and 2). In addition, these specimens showed indeterminate and definite rifampin (RMP) resistance, respectively (Table 1, samples 1 and 2). Since the patient had no history of TB and was from Switzerland (a low MDR TB incidence setting), based on previous reports of false RMP resistance assay results (2, 3), the clinician doubted the accuracy of the Xpert-MTB/ Rif RMP results. Therefore, an additional four sputum samples were submitted to the Swiss National Reference Center for Mycobacteria for rapid confirmation before initiation of MDR TB therapy. Further patient testing revealed HIV positivity.The four additional sputum specimens (Table 1, samples 3 to 6) were acid-fast smear positive by the Ziehl-Neelsen method (4), and Xpert-MTB/Rif testing detected the presence of M. tuberculosis complex. Surprisingly, all of the samples were scored RMP susceptible by the molecular assay (Table 1). In order to resolve the discrepant Xpert-MTB/Rif results and to rapidly confirm or rule out MDR TB, direct rpoB sequencing of the 81-bp core region and additional molecular screening for isoniazid (INH) resistance were performed as described previously (3, 5) and revealed rpoB Leu(CTG)533Pro(CCG) and katG Ser(AGC)315Thr(ACC) mutations, respectively, in all four specimens. Growth detection and quantitative phenotypic drug susceptibility testing (DST) for firstand second-line antituberculosis drugs with the MGIT 960 system and EpiCenter software with the TB eXiST module (Becton, Dickinson Microbiology Systems, Sparks, MD) were performed as described earlier (6). Quantitative DST identified resistance to RMP at 0.5 g/ml and susceptibility at 1.0, 4.0, and 20 g/ml, and resistance to rifabutin at 0.1 g/ml and susceptibility at 0.4 and 2.0 g/ml. DST for INH showed resistance at 0.1 and 1.0 g/ml and intermediate resistance at 3.0 and 10.0 g/ml. No drug resistance was identified by conventional DST for other first-and second...
We report four epidemiologically unrelated cases of KPC-carrying Klebsiella pneumoniae identified in Switzerland between May 2009 and November 2010. Three cases were transferred from Italy (two KPC-3, one KPC-2) and one from Greece (KPC-2). Resistance to colistin and doxycycline emerged in one KPC-3carrying K. pneumoniae strain during therapy. These results demonstrate ongoing dissemination of KPC throughout Europe. Rapid and reliable identification of KPC and implementation of control measures is essential to limit spread.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.